Consumer Staples · Converted Paper & Paperboard Prods (No Contaners/Boxes)

KMB Kimberly-Clark SEC Filings & Insider Trading Activity 2026

company
CIK 55785116 filings
S&P 500

KMB at a glance

Kimberly-Clark (KMB, SEC CIK 55785) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Kimberly-Clark (KMB) reported revenue of $16.4 billion (down 18.0% from FY2024) and net income of $2.0 billion. Diluted EPS was $6.07.
  • As of September 30, 2026, 51 institutional investment managers tracked by SignalX reported holding Kimberly-Clark (KMB) shares worth $14.7 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$16.4B
−18.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
51 funds
$14.7B · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: global manufacturing and marketing of personal care, family care, and professional products with leading brands in 175+ countries
  • New strategic focus: 2024 Transformation Initiative emphasizing proprietary innovation, margin optimization, and organizational agility for growth
  • Major corporate transactions: agreement to acquire Kenvue, Inc. for $6.7 billion plus 280 million shares; formed joint venture divesting 51% of International Family Care and Professional segment for $1.7 billion
  • Employee base steady at ~36,000 with 35% in North America and half in manufacturing/distribution roles
  • Sustainability commitment: execution of climate goals approved by SBTi, targeting reduced fossil fuel plastics, forest fiber use, and greenhouse gas emissions with $150 million environmental compliance spend expected in 2026

Risk Factors

  • Regulatory risk from tightening data privacy and cybersecurity laws worldwide, increasing compliance costs and potential liabilities related to breaches of consumer data
  • Geopolitical exposure in Russia and surrounding region due to war in Ukraine, with operation curtailed and assets at risk of impairment
  • Supply chain vulnerability from sole-source commodity suppliers and third-party manufacturers, risking production delays and cost increases
  • Competitive pressure from private label manufacturers with lower production costs and e-commerce distribution intensifying market share threat
  • Financial risk of credit rating downgrade increasing borrowing costs and reducing access to commercial paper market for funding

Management Discussion & Analysis

  • Net sales $16.45B, down 2.1% YoY; organic sales up 1.7% driven by 2.5% volume growth, offset by divestitures and currency impacts
  • Gross margin 36.0% vs 37.4%, down 140 bps; operating profit $2.35B, down 12.9%; adjusted operating profit $2.73B, flat YoY
  • North America segment: sales $10.75B (-2.4%), operating profit $2.55B (+0.4%); International Personal Care sales $5.69B (-0.9%), operating profit $796M (-3.6%)
  • Operating cash flow $2.8B, down from $3.2B; ongoing capital allocation includes $1.7B expected from IFP joint venture sale, transformation initiative costs approx. $1.5B pre-tax
  • Management focused on 2024 Transformation Initiative to achieve $3B gross productivity savings by 2026; risks include birth rate declines, competitive pressures, input cost volatility, geopolitical uncertainties including Russia and Ukraine conflict impacts

AI summary of the KMB 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Kenvue Acquisition integration: complex system consolidation could disrupt demand fulfillment and financial reporting
  • OTC product safety: oral phenylephrine removal could require reformulation or withdrawal of Sudafed PE and Tylenol Cold & Flu
  • Regulatory compliance: expanded OTC operations require cGMP compliance across company and third-party manufacturing facilities
  • Supply continuity: transition away from J&J manufacturing could increase defects, quality issues, and delivery costs
  • Indemnification exposure: talc claims outside the United States and Canada remain Kenvue’s responsibility with unquantifiable liability

Management Discussion & Analysis

  • Q3 revenue $4,134M, down 0.4% YoY from $4,150M; organic sales declined 1.3%
  • Gross margin 34.9% vs 36.0% YoY; adjusted gross margin 35.5% vs 36.8%
  • North America strongest: sales $2,738M, up 0.9%; International Personal Care weakest, sales $1,396M, down 2.8%
  • Operating cash flow $2.4B nine-month, up from $1.8B; capital spending $1.0B vs $741M
  • China diaper disruption remains a near-term headwind; incremental Middle East input costs estimated at approximately $250 for the year

AI summary of the KMB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Exhibit 99.1 reports Kimberly-Clark’s results for the quarter ended September 30, 2026
  • Investors should review the earnings release for revenue, profitability, guidance and operating drivers

Item EX-99.1: Item EX-99.1

  • Q3 net sales $4.1B, down 0.4%, with organic sales down 1.3% amid China disruption and North American inventory headwinds
  • Adjusted EPS from continuing operations $1.70, up 17.2%, helped by lower interest expense and adjusted tax rate
Filed Nov 4, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Financial obligation arises from the material agreement described in Item 1.01
  • Investors must review Item 1.01 for borrowing amount, terms, maturity and purpose

Item 1.01: Entry into a Material Definitive Agreement

  • KMB assumed $7.0B of Kenvue unsecured senior notes across maturities from 2028 through 2063
  • Exchange retired $6.376B of Kenvue notes, leaving only $623.961M outstanding as Kenvue obligations

Item 3.03: Material Modification to Rights of Security Holders

  • Rights modification tied to Kenvue notes assumption and exchange offers
  • Investors should review Item 1.01 for affected securities, consent terms and potential ownership implications

Item 8.01: Other Events

  • Final results announced for exchange offers and consent solicitations
  • Investor impact depends on tender participation and approved consent outcomes

Item EX-99.1: Item EX-99.1

  • Exchange offers attracted $6.376 billion of Kenvue notes, representing 90.8% of $7.0 billion outstanding
  • Kimberly-Clark expected to issue up to $7.0 billion of matching-rate, unsecured senior notes, increasing consolidated debt obligations
Filed Nov 2, 2026Full analysis →

Item 2.01: Completion of Acquisition or Disposition of Assets

  • K-C completed its acquisition of Kenvue, adding Kenvue’s consumer-health business to Kimberly-Clark’s portfolio
  • Kenvue shareholders received 0.14625 K-C shares plus $3.50 cash per share

Item 2.05: Costs Associated with Exit or Disposal Activities

  • Kenvue Integration Program targets operating profit synergies by 2030, with actions underway through December 31, 2029
  • Approximately $3.1 billion pre-tax charges, including $2.5 billion cash and $0.6 billion non-cash

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Three former Kenvue directors joined K-C’s board, with planned shareholder nomination at the 2027 annual meeting
  • Board turnover created vacancies for the Kenvue appointees, with no departures attributed to company disagreements

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • Amended bylaws effective November 2, 2026, upon completion of the Mergers
  • Tighter advance-notice and disclosure rules for stockholder proposals and director nominations

Item 7.01: Regulation FD Disclosure

  • K-C announced completion of the Mergers on November 2, 2026, marking a major corporate transaction milestone
  • Integration of Kenvue now becomes the key execution focus, with potential synergies and cost savings dependent on successful integration

Item EX-99.1: Item EX-99.1

  • Kenvue acquisition closed November 2, 2026, transforming KMB into a global consumer health and wellness platform
  • Kenvue holders received $3.50 cash plus 0.14625 KMB shares per share, creating cash funding needs and shareholder dilution

AI summaries of KMB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KMB

Don't miss the next KMB filing

  • Alerts as it files. A push when KMB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KMB, by share count.
  • Ask anything. An AI agent that reads every KMB filing and answers with sources.

KMB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MERLO LARRY JANov 2, 2026-
CULVER JOHNANov 2, 2026-
ALLISON RICHARD E JRANov 2, 2026-
Perry KirkANov 2, 2026-
Mahlan DeirdreANov 2, 2026-
Hsu Michael D.ANov 2, 2026-
CULVER JOHNANov 2, 2026-
Carmichael John PatrickMOct 31, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$20.1B$16.4B
Gross Profit$7.0B$7.2B$5.9B
Operating Income-$3.2B$2.4B
Net Income$1.8B$2.5B$2.0B
Gross Margin-35.8%36.0%
Op. Margin-16.0%14.3%
Net Margin-12.7%12.3%
Balance Sheet
Total Assets$17.3B$16.5B$17.1B
Equity-$840.0M$1.5B
ROE-303.0%134.6%
Per Share
EPS$5.21$7.55$6.07
Cash Flow
Operating CF-$3.2B$2.8B

Source: XBRL data in Kimberly-Clark (KMB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KMB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KMB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202651$14.68B
Q2 202652$17.75B
Q1 202651$14.36B
Q4 202551$14.50B
Q3 202554$17.70B
Q2 202553$17.61B
Q1 202552$13.57B
Q4 202448$10.66B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 412 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KMB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Nov 4, 2026--
4Nov 4, 2026--
8-KNov 4, 2026Analysis-
4Nov 4, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 2, 2026--
8-KNov 2, 2026Analysis-
4Nov 2, 2026--
8-KOct 29, 2026Analysis-
8-KOct 28, 2026Analysis-
8-KOct 20, 2026Analysis-
8-KOct 15, 2026Analysis-
8-KOct 13, 2026Analysis-
8-KOct 1, 2026Analysis-
8-KSep 28, 2026Analysis-
8-KAug 4, 2026Analysis-
4Aug 4, 2026--
10-QAug 4, 2026Analysis
4Aug 4, 2026--
8-KMay 14, 2026Analysis
SC 13GMay 12, 2026-

Related Consumer Staples companies

All Consumer Staples →

KMB SEC filings: frequently asked questions

Which institutions hold KMB stock?

As of September 30, 2026, the largest Kimberly-Clark (KMB) holders among the 13F filers tracked by SignalX were BlackRock ($3.1 billion), Vanguard Capital Management LLC ($2.1 billion), State Street Corp ($2.0 billion), Vanguard Portfolio Management LLC ($1.6 billion), Morgan Stanley ($736.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was KMB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Kimberly-Clark (KMB) reported revenue of $16.4 billion (down 18.0% from FY2024) and net income of $2.0 billion. Diluted EPS was $6.07. The figures come from the XBRL data in the 10-K.

What are the main risks in KMB's latest 10-K?

In the 10-K filed February 12, 2026, Kimberly-Clark (KMB) flagged: Regulatory risk from tightening data privacy and cybersecurity laws worldwide, increasing compliance costs and potential liabilities related to breaches of consumer data. Geopolitical exposure in Russia and surrounding region due to war in Ukraine, with operation curtailed and assets at risk of impairment. (AI summary of the Risk Factors section.)

What did KMB report in its latest 8-K?

Kimberly-Clark (KMB) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 reports Kimberly-Clark’s results for the quarter ended September 30, 2026.

What are the latest KMB SEC filings?

Kimberly-Clark (KMB) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 4, 2026.

What is KMB's SEC CIK number?

Kimberly-Clark (KMB)'s SEC Central Index Key (CIK) is 55785. EDGAR lists every KMB filing under that number.

Ask anything about KMB

The research agent reads KMB's filings, financials, insider trades and 13F holders, then answers with sources.